|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Opdivo
gptkb:Yervoy
|
|
gptkbp:activities
|
immune checkpoint inhibition
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:nivolumab
radiation therapy
chemotherapy
targeted therapy
|
|
gptkbp:clinical_trial
|
Phase III
advanced melanoma
NC T02224781
NC T00094653
NC T01420965
NC T01844505
NC T03070308
|
|
gptkbp:contraindication
|
autoimmune diseases
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
gptkb:James_P._Allison
Yale researchers
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:education_institution
|
gptkb:University
|
|
gptkbp:effective_date
|
gptkb:2011
|
|
gptkbp:government_type
|
Biologics License Application
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ipilimumab
|
|
gptkbp:indication
|
unresectable or metastatic melanoma
|
|
gptkbp:ingredients
|
gptkb:ipilimumab
|
|
gptkbp:invention
|
2026
patented
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
thyroid function tests
renal function tests
|
|
gptkbp:is_used_for
|
treatment of melanoma
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
gptkb:Yervoy
|
|
gptkbp:pharmacokinetics
|
T-cell activation
long half-life
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
gptkb:vaccine
clinical trials
oncology
|
|
gptkbp:side_effect
|
hepatitis
dermatitis
immune-related adverse events
pneumonitis
colitis
endocrinopathies
thyroid dysfunction
nephritis
|
|
gptkbp:targets
|
gptkb:CTLA-4
|
|
gptkbp:traded_on
|
gptkb:Yervoy
|
|
gptkbp:year_created
|
gptkb:2000
|